EMEA-002884-PIP01-20 - paediatric investigation plan

Recombinant humanised monoclonal immunoglobulin G4, with specificity for human tau (UCB0107)
PIPHuman

Key facts

Active Substance
Recombinant humanised monoclonal immunoglobulin G4, with specificity for human tau (UCB0107)
Therapeutic area
Neurology
Decision number
P/0061/2021
PIP number
EMEA-002884-PIP01-20
Pharmaceutical form(s)
Solution for infusion
Condition(s) / indication(s)
Treatment of progressive supranuclear palsy
Route(s) of administration
Intravenous use
Contact for public enquiries

UCB Pharma S.A.

E-mail: UCBCares.IE@ucb.com
Tel. +353 1463 2371

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page